XBiotech (NASDAQ:XBIT) is a clinical-stage biopharmaceutical company developing human antibodies to treat cancer and other inflammatory-driven diseases. The company’s core technology, the True Human™ antibody platform, enables the discovery and development of monoclonal antibodies that mimic the human immune response without the need for genetic humanization. XBiotech’s lead therapeutic candidate targets interleukin-1 alpha (IL-1α), a key mediator of inflammation associated with tumor growth and chronic disease.
The company’s most advanced program, Xilonix® (MABp1), is a first-in-class anti-IL-1α antibody that has completed Phase 3 clinical trials in metastatic colorectal cancer patients. Data from these studies demonstrated potential benefits in overall survival, symptom control and quality of life measures. XBiotech is also exploring Xilonix® in additional oncology settings as well as in post-surgical inflammation and other conditions driven by IL-1α–mediated pathways.
Beyond its lead candidate, XBiotech is advancing a diversified pipeline of True Human™ antibodies against novel targets in both oncology and inflammatory diseases. The company conducts clinical development programs in North America and Europe, collaborating with research hospitals and cancer centers to evaluate therapeutic potential across multiple indications. Preclinical studies are ongoing to expand the platform into other areas of unmet medical need.
Founded in 2005 by entrepreneur John Simard, XBiotech is headquartered in Austin, Texas, with research operations in Canada and Europe. Laurent Fischer serves as Chief Executive Officer, overseeing corporate strategy, clinical development and manufacturing partnerships. The company’s leadership combines expertise in antibody engineering, clinical oncology and regulatory affairs to advance its pipeline toward potential commercialization.
